Lv41
460 积分 2024-02-08 加入
OS-030 Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B: end of study results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
1小时前
已完结
Hepatitis B
1小时前
已完结
Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion
13天前
已完结
Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysis
13天前
已完结
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
13天前
已完结
Pharmacologic Inhibition of Epidermal Growth Factor Receptor Suppresses Nonalcoholic Fatty Liver Disease in a Murine Fast‐Food Diet Model
19天前
已完结
SIMPLE Is an Endosomal Regulator That Protects Against NAFLD by Targeting the Lysosomal Degradation of EGFR
19天前
已完结
Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis
19天前
已完结
Inflammatory liver diseases and susceptibility to sepsis
20天前
已完结
Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis
29天前
已完结
皖公网安备34019202002308
